We are a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies. Our vision is to deliver on the promise of fast and capital-efficient development of gene therapies in rare diseases by leveraging de-risked platforms, such as capsids and routes of administration, and optimised, proprietary vector constructs.